EXPRESSION OF SOME IMMUNOLOGIC MARKERS AND THE RELATION BETWEEN TUMOUR CELL LINEAGE WITH HISTOPATHOLOGY IN NON - HODGKIN LYMPHOMA

Background: Non - Hodgkin lymphoma is one of the two most common types of lymphoma, accounting for 85% and one of the most ten common cancers in the world as well as in Vietnam. The application of immunohistochemistry besides the histopathology for the tumours cell lineage diagnosis as well as the relation between the cell lineage with histopathology were very important for the prognosis and therapy orientation. Objectives: - To describe the gender, location and the malignant grade in patients with non – Hodgkin lymphôma; - To determine the expression of some immunologic markers, the relation between tumour cell lineage and histopathology in patients with non - Hodgkin lymphoma. Materials and method: This cross-sectional study was carried out on 60 patients with non- Hodgkin lymphoma diagnosed definitely by histopathology and classified as B, T cell by immunohistochemistry at Hue Central Hospital and Hue University Hospital. Results: The ratio of male/female for the non-Hodgkin lymphoma was 1.14/1, non - Hodgkin lymphoma appeared at lymph node was the most common (51.7%), at the extranodal site was relatively high 48.3%. The intermediate malignancy grade of non - Hodgkin lymphoma was the highest proportion accounting for 85%, then the low and the high ones 8.3% and 6.7% respectively. Immunophenotype by 5 markers including LCA, CD3, CD20, CD79a and CD45RO showed that: the B-cell non-Hodgkin lymphoma was predominant type (85%) and appeared more frequent as intermediate or low grade of malignancy, T - cell non – Hodgkin lymphoma was 13.3% and under the high orientation of malignant grade, unclassified type 1.7%; There were no relation between the tumours cell lineage and the gender or the original location of the tumours as well. Conclusion: The application of immunohistochemistry by 5 markers: LCA, CD3, CD20, CD79a and CD45RO was able to divide the tumour cell as the B or T cell of the non – Hodgkin lymphoma which was for for the prognosis and for the better treatment orientation as well. Key words: Lymphoma, non-Hodgkin lymphoma, grade, histopathology, immunohistochemistry, cell lineage

Download Full-text

STUDY OF HISTOPATHOLOGY IN PATIENTS WITH HODGKIN AND NON - HODGKIN LYMPHOMA

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2016.3.9 ◽

2016 ◽

pp. 59-65 ◽

Cited By ~ 1

Author(s):

Van Mao Nguyen

Keyword(s):

Lymph Node ◽

Hodgkin Lymphoma ◽

Cross Sectional Study ◽

University Hospital ◽

Cross Sectional ◽

Histopathological Classification ◽

Non Hodgkin Lymphoma ◽

Key Words Lymphoma ◽

Malignant Grade

Background: Lymphoma is one of the most ten common cancers in the world as well as in Vietnam which has been ever increasing. It was divided into 2 main groups Hodgkin and non – Hodgkin lymphoma in which non-Hodgkin lymphoma appeared more frequency, worse prognosis and different therapy. Objectives: - To describe some common characteristics in patients with non – Hodgkin lymphoma; - To determine the proportion between Hodgkin and non- Hodgkin lymphoma, histopathological classification of classical Hodgkin by modified Rye 1966 and non-Hodgkin lymphoma by Working Formulation (WF) of US national oncology institute 1982. Materials and Method: This cross-sectional study was conducted on 65 patients with Hodgkin and non- Hodgkin lymphoma diagnosed definitely by histopathology at Hue Central Hospital and Hue University Hospital. Results:. The ratio of male/female for the non-Hodgkin lymphoma was 1.14/1, the most frequent range of age was 51-60 accounting for 35%, not common under 40 years. Non - Hodgkin lymphoma appeared at lymph node was the most common (51.7%), at the extranodal site was rather high 48.3%. The non - Hodgkin lymphoma proportion was predominant 92.3% comparing to the Hodgkin lymphoma only 7.7%; The most WF type was WF7 (53.3%), following the WF6 18,3% and WF5 11,7%; The intermediate malignancy grade of non- Hodgkin lymphoma was the highest proportion accouting for 85%, then the low and the high one 8.3% and 6.7% respectively. Conclusion: The histopathological classification and the malignant grade of lymphoma for Hodgkin and non - Hodgkin lymphoma played a practical role for the prognosis and the treatment orientation, also a fundamental one for the modern classification of non - Hodgkin lymphoma nowadays. Key words: lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, classication, grade, histopathology, lymph node

Download Full-text

Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases

Blood ◽

10.1182/blood-2012-07-440073 ◽

2012 ◽

Vol 120 (24) ◽

pp. 4795-4801 ◽

Cited By ~ 68

Author(s):

Javier A. Laurini ◽

Anamarija M. Perry ◽

Eugene Boilesen ◽

Jacques Diebold ◽

Kenneth A. MacLennan ◽

...

Keyword(s):

T Cell ◽

South America ◽

B Cell ◽

Hodgkin Lymphoma ◽

B Cell Lymphoma ◽

Epidemiologic Studies ◽

Geographic Region ◽

Low Grade ◽

Non Hodgkin Lymphoma ◽

Objective Evidence

Abstract The distribution of non-Hodgkin lymphoma (NHL) subtypes differs around the world but a systematic study of Latin America has not been done. Therefore, we evaluated the relative frequencies of NHL subtypes in Central and South America (CSA). Five expert hematopathologists classified consecutive cases of NHL from 5 CSA countries using the WHO classification and compared them to 400 cases from North America (NA). Among the 1028 CSA cases, the proportions of B- and T-cell NHL and the sex distribution were similar to NA. However, the median age of B-cell NHL in CSA (59 years) was significantly lower than in NA (66 years; P < .0001). The distribution of high-grade (52.9%) and low-grade (47.1%) mature B-cell NHL in CSA was also significantly different from NA (37.5% and 62.5%; P < .0001). Diffuse large B-cell lymphoma was more common in CSA (40%) than in NA (29.2%; P < .0001), whereas the frequency of follicular lymphoma was similar in Argentina (34.1%) and NA (33.8%), and higher than the rest of CSA (17%; P < .001). Extranodal NK/T-cell NHL was also more common in CSA (P < .0001). Our study provides new objective evidence that the distribution of NHL subtypes varies significantly by geographic region and should prompt epidemiologic studies to explain these differences.

Download Full-text

Efficacy and safety of CAR19/22 T-cell “cocktail” therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.2534 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 2534-2534

Author(s):

Liang Huang ◽

Na Wang ◽

Chunrui Li ◽

Yi Xiao ◽

Yang Cao ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Hodgkin Lymphoma ◽

Low Grade ◽

Efficacy And Safety ◽

T Cell Therapy ◽

Overall Response ◽

Non Hodgkin Lymphoma ◽

The Impact

2534 Background: Antigen escape relapse has emerged as a major challenge for long-term disease control post CD19-directed therapies, to which dual-targeting of CD19 and CD22 has been proposed as a potential solution. Methods: Between Mar 2016 and Jan 2018, we conducted a pilot study (ChiCTR-OPN-16008526) in 38 patients (pts), who had refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), to evaluate the efficacy and safety of sequential infusion of anti-CD19 and anti-CD22, two single-specific, third-generation CAR19/22 T-cell “cocktail”. The cutoff date for data collection was Apr 30, 2018. Results: At a minimum follow-up of 3 months (mos), 26 of the 36 evaluable pts achieved an overall response (ORR), including 18 with a complete response (CR) and 8 with a partial response (PR). The ORR at mo 3 was consistent in different subgroups, irrespective of pathologic subtypes, cell of origin, cytogenetic or genomic aberrations. At the data cutoff, 15 of the 18 pts who had a CR at mo 3 maintained their responses, 2 of 8 pts who had a PR within 3 mos continued to have a CR without additional therapies. Collectively, the best ORR was 83.3%, with a best CR rate of 55.5% and a best PR rate of 27.8%. With a median follow-up of 5.3 mos (range, 0.4 to 16.2), the median PFS was 5.8 mos, and the median OS was not reached (NR). Pts received therapy at first relapse had better PFS than those who received therapy at the time with primary refractory diseases or at multiple relapses. Notably, pts who achieved an overall response at mo 3 (R3m) had significantly extended PFS and OS when compared with pts who did not. Repeated biopsy and IHC was conducted in 3 of the 13 pts. However, loss of CD19 or CD22 was not detected. Of the 9 pts with IgH/MYC translocation, with a median follow-up of 10.1 mos, the median PFS and median OS were NR. At data cutoff, 7 pts who had achieved R3m maintained their responses, including all the 4 pts with double-hit lymphoma. However, of the 10 pts with del(17p) or TP53 mutation, with a median follow-up of 5.3 mos (range, 2.7 to 14.5), the median PFS was 3.6 mos and the median OS was 9.9 mos. All pts experienced reversible CRS, with 21.1% were of high-grade. Neurotoxicity developed in 13.2% pts and were all low-grade. Conclusions: Our results indicated that sequential infusion of CAR19/22 T-cell is efficient and safe for pts with B-NHL. Dual antigen targeting is a promising approach to circumvent antigen loss relapse after CAR T-cell therapy. The impact of genetic subtypes and clinical parameters further underscores the critical importance of personalized immunotherapies. Clinical trial information: ChiCTR-OPN-16008526.

Download Full-text